Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug study offers lifeline to patients still benefiting from treatment

NCT ID NCT05629234

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study allows cancer patients who were already taking osimertinib in a previous trial and are still benefiting from it to continue receiving the medication. It tracks safety and side effects while patients keep taking the drug. The goal is to provide continued access to treatment that's working for them.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Beijing, 100142, China

  • Research Site

    Chongqing, 400042, China

  • Research Site

    Yangzhou, 225001, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Villejuif, 94805, France

  • Research Site

    George Town, 10450, Malaysia

  • Research Site

    Johor Bahru, 81100, Malaysia

  • Research Site

    Kuantan, 25100, Malaysia

  • Research Site

    Kuching, 93586, Malaysia

  • Research Site

    Szczecin, 70-419, Poland

  • Research Site

    Cheongju-si, 28644, South Korea

  • Research Site

    Donggu, 44033, South Korea

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seongnam-si, 13620, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Seoul, 5505, South Korea

  • Research Site

    Kaohsiung City, 83301, Taiwan

  • Research Site

    Taichung, 40705, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Tainan, 736, Taiwan

  • Research Site

    Taipei, 112201, Taiwan

  • Research Site

    Taoyuan District, 333, Taiwan

  • Research Site

    Nottingham, NG5 1PB, United Kingdom

Conditions

Explore the condition pages connected to this study.

CANCER